Matthew R Sullivan
Overview
Explore the profile of Matthew R Sullivan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sathyanarayana S, Bickford M, Smuliac N, Tonseth K, Murad F, Bao J, et al.
Cancer Genet
. 2025 Feb;
292-293:111-115.
PMID: 39999580
We present a detailed cytogenomic analysis from a patient with suspected acute promyelocytic leukemia (APL), based on morphological and immunophenotypic characteristics. Initial testing with fluorescence in situ hybridization (FISH) and...
2.
Sullivan M, White R, Ravi D, Kanetkar N, Fridman I, Ekenseair A, et al.
Cell Death Dis
. 2024 Jan;
15(1):18.
PMID: 38195589
For over two decades, Rituximab and CHOP combination treatment (rCHOP) has remained the standard treatment approach for diffuse large B-cell lymphoma (DLBCL). Despite numerous clinical trials exploring treatment alternatives, few...
3.
Fridman I, Kostas J, Gregus M, Ray S, Sullivan M, Ivanov A, et al.
Acta Biomater
. 2021 Jun;
132:473-488.
PMID: 34153511
Cancer is driven by both genetic aberrations in the tumor cells and fundamental changes in the tumor microenvironment (TME). These changes offer potential targets for novel therapeutics, yet lack of...
4.
Aluri K, Hossain M, Kanetkar N, Miller B, Dowgiallo M, Sivasankar D, et al.
Bioconjug Chem
. 2021 Feb;
32(3):584-594.
PMID: 33606505
We recently reported that cyclic thiosulfinates are cysteine selective cross-linkers that avoid the "dead-end" modifications that contribute to other cross-linkers' toxicity. In this study, we generalize the chemistry of cyclic...
5.
Barnett J, Sullivan M, Long J, Tang D, Nguyen T, Ben-Amotz D, et al.
Nat Chem
. 2020 May;
12(7):589-594.
PMID: 32424255
There are many open questions regarding the hydration of solvent-exposed non-polar tracts and pockets in proteins. Although water is predicted to de-wet purely repulsive surfaces and evacuate crevices, the extent...
6.
Sullivan M, Yao W, Gibb B
Supramol Chem
. 2019 Sep;
31(3):184-189.
PMID: 31555042
Although computer-aided drug design has greatly improved over time, its application in the pharmaceutical industry is still limited by the accuracy of association constant predictions. Towards improving this situation, the...
7.
Sullivan M, Yao W, Tang D, Ashbaugh H, Gibb B
J Phys Chem B
. 2018 Jan;
122(5):1702-1713.
PMID: 29373793
The interactions between nonpolar surfaces and polarizable anions lie in a gray area between the hydrophobic and Hofmeister effects. To assess the affinity of these interactions, NMR and ITC were...
8.
Sullivan M, Sokkalingam P, Nguyen T, Donahue J, Gibb B
J Comput Aided Mol Des
. 2016 Jul;
31(1):21-28.
PMID: 27432339
In participation of the fifth statistical assessment of modeling of proteins and ligands (SAMPL5), the strength of association of six guests (3-8) to two hosts (1 and 2) were measured...
9.
McKenna D, Sullivan M, Hill J, Lowrey C, Brown J, Hickman J, et al.
J Community Support Oncol
. 2016 Feb;
13(9):316-22.
PMID: 26859751
Background: About 1 in 7 of all hospitalized patients is readmitted within 30 days of discharge. The cost of readmissions is significant, with Medicare readmissions alone costing the health care...
10.
Reagan J, Sullivan M, Winer E, Lansigan F, Cardin M, Castillo J
Leuk Res
. 2015 Jun;
39(8):812-7.
PMID: 26045177
Introduction: During induction daunorubicin intensification from 45 mg/m(2)/day to 90 mg/m(2)/day has shown improved response and survival rates in AML patients. We retrospectively reviewed outcomes of daunorubicin 60 mg/m(2)/day (DNR60)...